Reported Sunday, AbbVie Plans ESMO 2026 Update Showing ABBV-706 Achieved 56% ORR And 12.4-Month Median OS In 2L+ Small Cell Lung Cancer, With 82% ORR In 2L-Only Patients

AbbVie plans to present an update at ESMO 2026, showcasing that its drug ABBV-706 achieved a 56% overall response rate (ORR) and a median overall survival (OS) of 12.4 months in patients with second-line or greater small cell lung cancer, with an 82% ORR in second-line-only patients. The company will highlight data from seven oncology assets, emphasizing its commitment to addressing diverse patient needs through advanced therapies. This marks AbbVie's largest presence at ESMO to date, featuring findings from both investigational and approved medicines.